![tert-Butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate: Case Study on Temperature-Controlled Degradation & Material Dispersion Formulation Optimization](/themes/simple/img/i-home.png "tert-Butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate: Case Study on Temperature-Controlled Degradation & Material Dispersion Formulation Optimization")
As a new-type foreign trade service provider driven by technology transformation and dual-wheel foreign trade operations, HiSiaddi has established a "1+2+3+4=1" service system and can supply raw materials from well-known original manufacturers for tert-butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate.
Endowed with R&D attributes, HiSiaddi, through technological transformation cooperation with factories and precise insight into market demands, frequently proposes formulation optimization schemes and application improvement recommendations for tert-butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate. Below is a consulting case of formulation optimization delivered by HiSiaddi for this product.
Please contact HiSiaddi customer service if you require further formulation optimization consulting services.
The client is Europharma SAS, a high-end pharmaceutical enterprise headquartered in Lyon, France, specializing in R&D and manufacturing of oral original hypoglycemic drugs and premium generics with sales coverage across the EU, fully adhering to EMA, FDA and ICH Q7 quality specifications. Its flagship product is saxagliptin formulation. The enterprise maintains annual procurement of 120 kg tert-butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate, the core chiral intermediate of saxagliptin, representing a mid-to-high-end European client with rigorous requirements for raw material performance, reaction compatibility and batch stability.
The client utilized the intermediate stably in small-scale trials with all indicators within specifications, yet switched to domestic bulk supply triggered persistent production abnormalities within its proprietary synthetic formulation and production lines: sustained decline in reaction yields, out-of-spec stereoisomeric impurities, abnormal material dissolution and precipitation, and inability to fix continuous production parameters. Multiple internal R&D adjustments to formulation ratios, production temperatures and feeding rhythms failed to resolve root causes, driving elevated raw material consumption and production costs. With impurity levels approaching EU Pharmacopoeia limits, the client faced risks during EMA on-site audits. The client subsequently commissioned HiSiaddi to conduct full-process technical investigations and deliver targeted formulation & production supporting optimization solutions.
HiSiaddi assembled a dedicated technical team specializing in organic synthesis, chiral process engineering and production operation maintenance. Cross-analysis of raw material test reports, client proprietary reaction formulations, continuous production line data and multi-batch feeding records identified four core technical issues and root causes:
1.
Mismatch between proprietary reaction formulations and raw material physical properties driving increased side reactions Featuring an aza-bicyclic bridged ring structure with high steric hindrance and sensitive chiral configurations, the intermediate was processed with a conventional single organic base as acid scavenger. Trace residual polar substances in domestic raw materials reacted with the alkaline system to generate multiple stereoisomeric impurities, depressing chiral purity from 99.9% to 99.6% and pushing single impurities above internal control thresholds. Imbalanced acid-base molar ratios further reduced main reaction conversion by 8%.
2.
3.
Single-component solvent system causing poor material dispersion and dissolution stability The client exclusively employed a single polar organic solvent. Uneven particle size distribution of intermediate powder induced local agglomeration and low-temperature precipitation within the reaction system. This created inconsistent reactor concentrations triggering localized over-reaction or incomplete conversion, while precipitated material adhered to equipment inner walls amplifying raw material loss and compromising purification efficiency during subsequent extraction and refining steps.
4.
5.
Misaligned temperature control & material residence parameters triggering structural degradation The intermediate exhibits weak thermal stability. The client’s production lines operated within conventional temperature ranges; prolonged medium-to-high temperature reactions induced ring-opening degradation of the bicyclic framework generating characteristic degradation impurities. Suboptimal continuous-flow residence durations and dropping rates further amplified impurity generation and severe batch-to-batch quality fluctuations.
6.
7.
Lack of flexible process windows unable to accommodate normal raw material batch variations Minor natural fluctuations in residual solvent levels and crystal morphology occur across different intermediate batches, yet the client operated fixed production parameters, requiring repeated readjustment of stirring speed, pH and feeding ratios for every production batch. This eliminated standardized workflow feasibility, drastically lowering production efficiency and impeding quality traceability.
8.
All optimizations followed core principles: no modification to the client’s core synthetic route, low transformation costs, compatibility with existing production lines and long-term operational stability. Four dimensions of adjustments (raw material fine-tuning, formulation improvement, production parameter calibration and standardized operating procedures) were developed and validated through multiple rounds of lab and pilot trials prior to full deployment.
HiSiaddi collaborated with its contracted domestic manufacturing partners to optimize post-treatment workflows without altering core synthetic processes: additional low-polarity solvent washing and gradient cooling recrystallization steps were implemented to selectively remove trace polar residual impurities. Tighter internal control thresholds for raw material moisture and residual solvents were enforced, alongside unified powder particle size and crystal form standards to minimize physical property deviations across batches and reduce downstream reaction interference.
· Compound acid scavenger replacing single-component system Retaining the client’s base formulation framework, a composite acid scavenger system substituted the single organic base, precisely matching the intermediate’s reaction activity to block stereoisomer and byproduct formation and restore chiral purity to acceptable ranges. Recalculated acid-base molar ratios recovered main reaction conversion to design benchmarks.
· Improved mixed solvent system Low-polarity co-solvents were blended into the primary solvent to tune overall system polarity, enhancing powder dispersion and dissolution, fully eliminating agglomeration and low-temperature precipitation phenomena and cutting equipment wall adhesion losses by 7%.
Combining thermal stability data of the intermediate and the client’s continuous-flow equipment characteristics, revised process windows were defined with lowered core reaction temperatures and segmented gradient temperature control. Synchronized adjustments to material dropping rates, reactor residence durations and stirring speeds prevented bicyclic framework degradation, stabilizing degradation impurities below detection limits. Floating parameter windows were introduced to accommodate minor natural raw material batch variations.
English-language full-process operating manuals, parameter comparison tables and abnormal condition prediction protocols were compiled based on optimized formulations and process parameters, specifying fine-tuning rules corresponding to varying raw material batches. HiSiaddi deployed on-site technical specialists to remotely support the client through three consecutive trial production batches, training workshop operators on revised workflows and establishing standardized operating protocols.
Post-implementation, reaction yields returned to design targets, stereoisomers and degradation impurities were stably controlled below EMA limits, and chiral purity maintained above 99.9%, with all test metrics surpassing internal client specifications.
Flexible process windows and standardized operating procedures eliminated repeated batch-by-batch parameter readjustment. More than ten consecutive mass production batches operated stably, lifting overall production efficiency by 9% and drastically cutting raw material losses.
Complete closed-loop documentation of optimization records, batch data and impurity traceability reports enabled the client to pass the EMA quarterly on-site audit with zero corrective actions.
The client’s Production & Technical Director stated that HiSiaddi accurately diagnosed core imbalances between raw material physical properties, legacy formulations and mass production processes. The optimized solutions seamlessly integrated with existing production equipment, delivered rapid implementation and sustained operational stability, effectively resolving dual risks of quality non-compliance and regulatory audit failure.
Building on this successful collaboration, the client maintained its original procurement volume, increased monthly purchasing frequency for the intermediate, and entrusted HiSiaddi with technical support and supply services for two additional premium heterocyclic intermediates, establishing a long-term technical synergy partnership.
tert-Butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate is a highly reactive chiral bridged-ring intermediate highly sensitive to reaction formulations, solvent systems, temperature and duration, representing a common technical pain point during mass manufacturing for premium pharmaceutical enterprises. The root cause of production abnormalities in this case was not inherent raw material quality defects, but mismatches between raw material physical characteristics, legacy formulations and mass production workflows.
Drawing deep expertise in the physicochemical properties of high-end pharmaceutical intermediates, synthetic reaction mechanisms and European pharmaceutical production models, HiSiaddi avoided full overhaul of the client’s proprietary processes and adopted an "adaptation & optimization" core strategy to sequentially adjust source raw materials, midstream formulations and downstream production parameters. This approach delivered thorough issue resolution while limiting transformation costs, safeguarding the client’s existing equipment, personnel and core synthetic workflows, and protecting premium pharmaceutical product quality and regulatory compliance thresholds. The case fully demonstrates the integrated core value of a foreign trade service provider combining supply chain management and professional technical services.
Please contact HiSiaddi customer service if you require further formulation optimization consulting services.
+86-13120989737 
info@hisiaddi.com 
English
